We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

Biohaven (NYSE:BHVN) shares traded higher on Wednesday after the company said its antibody-drug conjugate BHV-1510 with ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

May 29, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life ...

Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with non-dilutive capital as it prepares for a potential US launch of troriluzole for ...

May 10 (Reuters) - Pfizer Inc (PFE.N), opens new tab said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co (BHVN.N), opens new tab, making a big bet on its ability to ...

Matt Buten, Chief Financial Officer at Biohaven, commented, "We are pleased to have both the support and confidence of Oberland Capital, an exceptional partner with a proven track record in ...

NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative ...

Pfizer said it would pay $148.50 a share in cash for the Biohaven shares that it doesn’t already own, a nearly 79% premium to Monday’s closing price of $83.14 for the New Haven, Conn., ...

As a reminder, Biohaven Ltd. is a British Virgin Islands domiciled, New Haven, Connecticut headquartered clinical-stage biopharmaceutical concern focused on developing treatments for various ...

The last time I wrote about Biohaven (NYSE:BHVN) it was with respect to a Seeking Alpha article entitled "Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst." ...

Sept 23 (Reuters) - Biohaven's (BHVN.N), opens new tab drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more than 12% as the trial data ...